. 2019 Jul 18;12:5813–5822. doi: 10.2147/OTT.S174640

Table 1.

Elotuzumab for the treatment of multiple myeloma: Phase I–III clinical trials

Study	Phase	N	Regimen	ORR(%)	Median PFS
Elotuzumab monotherapy
Zonder et al 2012¹⁸	1	35	Elotuzumab (0.5–20 mg/kg)	0	-
Elotuzumab with Imids regimens
Lonial et al 2012¹⁹	1b	29	Elotuzumab (5–20 mg/kg)+Rd	82	32.9
Richardson et al 2015²⁰	2	36 37	Elotuzumab (10 mg/kg)+Rd Elotuzumab (20 mg/kg)+Rd	92 76
Lonial et al 2015²¹	3	321 325	Elotuzumab (10 mg/kg)+Rd Rd	79 66	19.4 14.9
Dimopoulos et al 2018²²	2	60 57	Elotuzumab (10 mg/kg)+Pd Pd	53 26	10.3 4.7
Mateos et al 2016²³	2	40	Elotuzumab (10 mg/kg)+TD	40	-
Elotuzumab with PI regimens
Jakubowiak et al 2012²⁴	1	28	Elotuzumab (2.5–20 mg/kg)+V	48
Jakuboviak et al. 201627²⁵	2	77 75	Elotuzumab (10 mg/kg)+VD VD	66 63	9.7 6.9

Abbreviations: N, number; ORR, objective response rate; PFS, progression-free survival; Rd lenalidomide and dexamethasone; TD, thalidomide and dexamethasone; V, bortezomib; VD, bortezomib and dexamethasone.